Clinical Trial Update: Superparamagnetic Iron Oxide for Sentinel Lymph Node Localization in Patients With Cutaneous Melanoma, a Randomized Phase III Multi-center Non- Inferiority Trial: MagMen-II [Phase 3]

View source ↗

Summary

A Phase III randomized non-inferiority trial evaluating superparamagnetic iron oxide for sentinel lymph node localization in cutaneous melanoma is not yet recru…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Superparamagnetic Iron Oxide

Snippet

Sponsor: Vastra Gotaland Region | Conditions: Melanoma (Skin Cancer) | Phase 3 | Status: NOT_YET_RECRUITING